O'Rourke D - Search Results

1

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.

Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, Pang B, Logan GE, McCavigan AM, O'Rourke D, McArt DG, McDade SS, Mills IG, Prise KM, Knight LA, Steele CJ, Medlow PW, Berge V, Katz B, Loblaw DA, Harkin DP, James JA, O'Sullivan JM, Kennedy RD, Waugh DJ. Jain S, et al. Ann Oncol. 2018 Jan 1;29(1):215-222. doi: 10.1093/annonc/mdx637. Ann Oncol. 2018. PMID: 29045551 Free PMC article.

2

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.

Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, Johnston PG, McKeown SR, Wilson RH, O'Sullivan JM, Waugh DJ. Wilson C, et al. Br J Cancer. 2008 Dec 16;99(12):2054-64. doi: 10.1038/sj.bjc.6604804. Epub 2008 Dec 2. Br J Cancer. 2008. PMID: 19050703 Free PMC article.

3

The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria.

Abogunrin F, O'Kane HF, Ruddock MW, Stevenson M, Reid CN, O'Sullivan JM, Anderson NH, O'Rourke D, Duggan B, Lamont JV, Boyd RE, Hamilton P, Nambirajan T, Williamson KE. Abogunrin F, et al. Cancer. 2012 May 15;118(10):2641-50. doi: 10.1002/cncr.26544. Epub 2011 Sep 14. Cancer. 2012. PMID: 21918968 Free article.

4

Ultrasound targeted microbubble destruction using docetaxel and Rose Bengal loaded Microbubbles for targeted Chemo-Sonodynamic therapy treatment of prostate cancer.

McKaig T, Logan K, Nesbitt H, Callan B, McKeown S, O'Sullivan JM, Kelly P, O'Rourke D, McHale AP, Callan JF. McKaig T, et al. Eur J Pharm Biopharm. 2023 Nov;192:196-205. doi: 10.1016/j.ejpb.2023.10.012. Epub 2023 Oct 18. Eur J Pharm Biopharm. 2023. PMID: 37858804

5

The need to embrace molecular profiling of tumor cells in prostate and bladder cancer.

Duggan BJ, McKnight JJ, Williamson KE, Loughrey M, O'Rourke D, Hamilton PW, Johnston SR, Schulman CC, Zlotta AR. Duggan BJ, et al. Clin Cancer Res. 2003 Apr;9(4):1240-7. Clin Cancer Res. 2003. PMID: 12684390 Review.

6

Collectives of diagnostic biomarkers identify high-risk subpopulations of hematuria patients: exploiting heterogeneity in large-scale biomarker data.

Emmert-Streib F, Abogunrin F, de Matos Simoes R, Duggan B, Ruddock MW, Reid CN, Roddy O, White L, O'Kane HF, O'Rourke D, Anderson NH, Nambirajan T, Williamson KE. Emmert-Streib F, et al. BMC Med. 2013 Jan 17;11:12. doi: 10.1186/1741-7015-11-12. BMC Med. 2013. PMID: 23327460 Free PMC article.

7

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. McCrudden CM, et al. PLoS One. 2015 Feb 17;10(2):e0118187. doi: 10.1371/journal.pone.0118187. eCollection 2015. PLoS One. 2015. PMID: 25689628 Free PMC article.

8

An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.

Sutton AJ, Lamont JV, Evans RM, Williamson K, O'Rourke D, Duggan B, Sagoo GS, Reid CN, Ruddock MW. Sutton AJ, et al. PLoS One. 2018 Aug 23;13(8):e0202796. doi: 10.1371/journal.pone.0202796. eCollection 2018. PLoS One. 2018. PMID: 30138462 Free PMC article.

9

Radiation-induced atypical squamous metaplasia of the urinary bladder mucosa with involvement of subepithelial tissue mimicking metastatic cervical squamous carcinoma.

Dillon KM, O'Rourke DM, McCluggage WG. Dillon KM, et al. Histopathology. 2005 Jan;46(1):105-6. doi: 10.1111/j.1365-2559.2005.02028.x. Histopathology. 2005. PMID: 15656893 No abstract available.

10

Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific.

Duggan B, O'Rourke D, Anderson N, Reid CN, Watt J, O'Kane H, Boyd R, Curry D, Evans M, Stevenson M, Kurth MJ, Lamont JV, Fitzgerald P, Ruddock MW. Duggan B, et al. Front Oncol. 2022 Sep 23;12:1009014. doi: 10.3389/fonc.2022.1009014. eCollection 2022. Front Oncol. 2022. PMID: 36212463 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

562 results

Search Page